Shore Capital Group Reiterates “House Stock” Rating for Roquefort Therapeutics (LON:COIL)

Roquefort Therapeutics (LON:COIL – Get Free Report)‘s stock had its “house stock” rating restated by investment analysts at Shore Capital Group in a research note issued on Monday, Marketbeat.com reports.

Roquefort Therapeutics Price Performance

LON COIL opened at GBX 7.60 on Monday. Roquefort Therapeutics has a one year low of GBX 6.75 and a one year high of GBX 12.50. The stock has a 50-day moving average of GBX 9.13 and a 200 day moving average of GBX 9.39. The company has a market capitalization of £32.44 million, a price-to-earnings ratio of -0.35 and a beta of 0.05. The company has a debt-to-equity ratio of 8.18, a quick ratio of 3.07 and a current ratio of 0.63.

Get Roquefort Therapeutics alerts:

About Roquefort Therapeutics

(Get Free Report)

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.

Read More

• Five stocks we like better than Roquefort Therapeutics
• Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
• Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
• AMD Chips Away at NVIDIA’s AI Throne
• Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?

Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.